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PREFACE
Gastric cancer is a disease with poor prognosis.  The incidence of 
esophageal cancer is increasing throughout the world in both sexes and it 
also carries a very poor prognosis. There is still  much to understand about 
the genes that contribute to the progression of above malignancies..
The  activated  estrogen  receptor  gene  mediates  inhibition  of  cell 
division, suppress growth of  genetically deranged cells and also effectively 
acts  as  a  tumour  suppressor  gene,  in  carcinogenesis.  In  upper 
gastrointestinal malignancies, the role of the Hormonal receptor, estrogen 
receptor is still under evaluation. 
The  identification  of  estrogen  receptor  is  not  only  an  important 
predictive test for the endocrine manipulation of the tumour, but also an 
essential target for the drug action. Control of estrogen receptor in breast 
cancer is well established now. A detail trial on endocrine manipulation of 
upper  gastro  intestinal  malignancies,  is  not  available  so  far.  For  this, 
detection of estrogen receptor is mandatory. This study addresses the above 
need.
INTRODUCTION
Hormones  are  important  regulators  of  growth.  By  stimulating 
proliferation, hormones may increase the risk of mutation and at the same 
time stimulate the replication of mutated cell. Thus Hormones are complete 
carcinogens. An excellent example is Enterochromaffin like cell carcinoid 
of  the  stomach,  which  is  caused  by  hypergastrinaemia,  and  where 
pathogenesis  is  diffuse  hyperplasia,  linear  and  nodular  hyperplasia, 
dysplasia, intramucosal carcinoid and invasive carcinoid (11).
Beatson's  original  observation  on  breast  cancer  regression  after 
ovariectomy published in 1896, provided the first insight into the hormone 
dependent nature of the tumours.  In 1960,  Jensen et  al  discovered the 
existence of estrogen receptor (ER) in the cytoplasm of human mammary 
cancer cells. In 1961, folca and others monitored in vivo uptake of synthetic 
radiolabelled estrogen, in breast tumors by administering tritiated hexestrol, 
to  women  about  to  undergo  mastectomy  and  subsequently  found  that, 
women who would respond to endocrine ablation had a greater uptake of 
radioactive hexestrol in their neoplasm than did non responding patients 
(2). Numerous studies have subsequently shown that approximately half of 
all biopsy specimen of malignant breast tumours contain estrogen receptor 
(3,4,5).
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Jensen and others proposed the estrogen receptor assay to predict 
responsiveness to endocrine therapy and this was subsequently refined by 
also measuring the progesterone receptor (6,7). The oncologist's use of 
these biochemical criteria (Presence of estrogen receptor and 
progesterone receptor)  has increased by twofold or three fold, the 
accuracy of selecting the patients with breast cancer who are most likely 
to respond objectively to endocrine manipulation (4,5).  Estrogen receptor 
positivity and their positive impact on the management of hormone 
dependent tumours like breast, ovary, uterine, prostatic cancer is well 
established only very few papers have been published about the estrogen 
receptor positivity in non-hormone dependent tumours like liver, 
stomach, pancreas, rectum and lung. 
In 1983, Tokunga et al first reported estrogen receptor expression in 
gastric cancer (10) but it role in gastric carcinogenesis remained unknown. 
Since then estrogen receptors are reported to be present in malignancies of 
non  reproductive  organs  like  liver  (12)  stomach  (13,14),  pancreas  (15) 
Rectum (14,16) and lung. 
There are  very few publications about the estrogen receptors status 
in  upper  gastrointestinal  malignancies.  Cited  publications  proved  the 
presence of estrogen receptors in esophageal carcinoma cell line (17)  and 
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gastric  carcinoma.   (10,19).   They also  proved that  17 ß,  estradiol  has 
growth inhibitory effect  on estrogen receptor positive esophageal  cancer 
cell line (18) and estrogen increases apoptosis in human gastric cancer cells 
(20).   Almost  all  the  publications  on  estrogen  receptor  in  upper 
gastrointestinal  malignancies  are  from  Japan  and  few  from  Western 
Countries that too  mostly proven in animal models.  To the best of our 
knowledge,  this  is  the  first  study  on  estrogen  receptor  status  in  upper 
gastrointestinal malignancies in this part of the world. 
Worldwide  gastric  cancer in the fourth most common cancer and 
second leading cause of cancer death (22,28). In India, Gastric cancer is the 
most  common cancer among all  and the most  common cause of cancer 
death. Worldwide esophageal cancer ranks fifth in the mortality rate among 
tumour  sites  (29).  In India,  esophageal  cancer is the 3rd most  common 
cancer in men and 5th most  common cancer in women. 
Recognition  of  estrogen  receptor  status  in  upper  gastro  intestinal 
malignancies will help us using hormonal therapy, even in situations where 
other modalities of treatment fail.  Existing studies reveal that the estrogen 
receptor positivity in upper gastro intestinal malignancies range from 0-
65%, depending on the method of study.
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In  this  study,  we  experimentally  identified  the  estrogen  receptor 
positivity  in  upper  gastrointestinal  malignancies,  which  are  the  most 
common  and  leading  killers  among  GI  malignancies  in  India  we  also 
analysed and compared our study results with international studies. 
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ESTROGEN RECEPTOR
In 1960, Jensen  et  al., first  proposed estrogen receptor,  based on 
pioneering  studies in immature rats, that proved radiolabelled  estradiol 
would bind preferentially in estrogen target tissues such as uterus, vagina 
and pituitary gland.  The rat  uterine estrogen receptor  was  subsequently 
isolated and shown to be an extractable estrogen binding protein (30,31). 
The estrogen receptor is a nuclear transcription factor, that is a member of 
the steroid receptor superfamily (32).
Recent studies have revealed the existence of two distinct estrogen 
receptors in our body, estrogen receptor  α and estrogen receptor ß. The 
genes for both receptors are encoded by 8 Exons, which are located on 
different chromosomes. The gene for estrogen receptor α found on the long 
arm of chromosome 6 (6q 25.1) and for estrogen receptor ß on chromosome 
14 (33).
While  both  estrogen  receptor  α and  estrogen  receptor   ß  bind 
estrogen as well as other agonists and antagonists, the two receptors have 
distinctly different localisation and concentration within our body. Estrogen 
receptor α is found in the liver, estrogen receptor ß in gastrointestinal tract 
and both receptors are distributed in cns, mammary gland, cardiovascular 
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system, urogenital tract and bone (34). The first complete human estrogen 
receptor ßcDNA was cloned and found to contain 530 aminoacids (35). 
Two of the most interesting sites on the estrogen receptor  molecule 
are its ligand binding domain (LBD) otherwise known as AF-2, and growth 
factor binding domain, otherwise known as AF-1. In addition, the DNA 
binding  domain  (DBD)  is  responsible  for  binding  at  estrogen  response 
elements (ERE) on the chromosome.
A subtle difference between the two receptors is in their ligand - 
binding pockets, in the substitution of Leu 338 in estrogen receptor α with 
met 384 in estrogen receptor ß (34).
In one study on immunolocalisation of estrogen receptor α and ß in 
gastric epithelium and enteric neurons, Estrogen receptor α and ß proteins 
were detected in the nuclei of fundic parietal cells and epithelial cells in the 
progenitor  zone.  In  the  antrum,  several  cells  are  immunoreactive  for 
estrogen receptor ß, in the  region containing stem cells and neuroendocrine 
cells but estrogen receptor α protein was not detected.
Both estrogen receptor  α and ß proteins were expressed in enteric 
neurons within the nucleus and cytoplasm, with specific punctate staining 
for estrogen receptor  in cell bodies and fibres (36).
6
FUNCTION
Estrogen interact with their nuclear receptor in target tissue cells to 
modulate hormone responsive gene expression. 
HORMONE (ESTROGEN)
DIFFUSE INTO NUCLEUS
BINDS TO HORMONE RECEPTOR
DISSOCIATES HEAT SHOCK PROTEIN FROM RECEPTOR AND 
CHANGE IN CONFIRMATION
DIMERIZATION OF HORMONE RECEPTOR MOLECULE
BIND TO DNA SEQUENCES IN THE VICINITY OF TARGET GENES 
CALLED "`HORMONE RESPONSIVE ELEMENT" (HRE)
In presence of agonist ligand estradiol 
and P 160 family Coactivator proteins 
SRC - 1  SRC - 2 SRC - 3
In presence of Antagonist ligand (4 
OH Tamoxifen) and Corepressor 
Proteins
Acetylation of histones results in 
derepression of  chromatin
Deacetylation of Histones results in 
repression of chromatin
Facilitates binding of transcription 
factors to promoter
Impairs access of critical 
transcription factors to template 
(promoter)
Increases Transcription Repress transcription
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FUNCTIONAL DIFFERENCES
Interestingly,  estrogen  receptor  α and  ß  when  complexed  with 
estrogen, were shown to signal in opposite ways from an AP-1 site, with 
estrogen activating transcription in the presence of estrogen receptor α and 
inhibiting transcription in the presence of estrogen receptor ß.
The location of estrogen receptors in gastric epithelium and enteric 
neurons imply that direct regulation of multiple cell types by estrogens may 
contribute to the modulation of gastric functions, that have been recognized 
during the estrous cycle and between sexes (36).
Estrogen  increases  apoptosis  in  human  gastric  cancer  cells  (20). 
Recently estrogen has  been found to stimulate  the expression of  trefoil 
peptides  in  the  stomach  (21,46),  which  play  a  key  role  in  mucosal 
protection through mucous barrier formation and in mucosal repair, through 
promotion of restitution after injury. Estrogen receptor genes may also act 
as tumour suppressor gene.
Most recent drugs targeted to estrogen receptors such as Tamoxifen, 
ICI-164384,  Raloxifene,  act  as  either  estrogen  receptor  agonist  or 
antagonist depending on species, tissues, and administered dose. 
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PURPOSE OF STUDY
In a recent study, global age specific pattern of the male to female 
ratio of gastric cancer suggests  basic biological  differences between the 
sexes,  (preventive effect  of  estrogen),  that  could explain the worldwide 
male predominance in the incidence of gastric cancer.(22) 
In Sweden, three case control studies and one cohort study conducted 
on postmenopausal  women all  indicated a  negative association  between 
longer  fertility  and  gastric  cancer  (23,24,25,26).  Further  in  a  placebo 
controlled randomized study on adjuvant treatment of breast cancer, there 
was an increased risk of gastric cancer among women, who received the 
drug tamoxifen, used mainly for its antiestrogen effect on estrogen receptor 
positive breast cancer (37).
Long arm of chromosome 6, containing estrogen receptor α gene is 
regarded as a site with frequent loss of heterozygosity (LOH) in gastric 
cancer.  Deletion  of  long  arm of  chromosome  6,  is  common  is  gastric 
carcinoma (38) suggesting the presence of tumour suppressor genes in this 
region  (45).  There  are  enough  publications  that  estrogen  receptor  may 
mediate inhibition of cell division and the activated estrogen receptor gene 
was reported to suppress growth of a neuroblastoma cell line (39).
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Introduction  of  estrogen  receptor  gene  into  estrogen  receptor 
negative  colon  carcinoma  cells  were  found  to  cause  marked  growth 
suppression (40). From a swedish study, they found that reduced risk of 
gastric  cancer  in  a  male  cohort  (Prostate  cancer  patients)  exposed  to 
estrogen. Studies also proved that growth inhibition of estrogen receptor 
positive esophageal cancer cell line, by 17ß estradiol (E2) is mediated by 
signal transduction induced by estrogen-estrogen receptor system (18).
Before recommending hormonal treatment for upper 
gastrointestinal malignancies we should know about the estrogen receptor 
status in India; thereby percentage of patients who would respond well is 
known. So we experimentally studied about estrogen receptor status with 
upper gastrointestinal endoscopy specimens by immunohistochemistry 
method.
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LACUNAE IN CURRENT KNOWLEDGE
The two isoforms of estrogen receptors (α and ß), have two different 
opposite  functions.  This  necessitates  us  to  identify  estrogen  receptor  ß 
separately which acts as tumour suppressor gene in the absence of estrogen 
receptor α (47), so that type of hormonal treatment (agonist/ antagonist) to 
be recommended is known.
Eventhough literature suggest that the effects of estrogen in stomach 
cancer  as  well  as  in  normal  stomach  might  be  mediated  by  estrogen 
receptor ß, the role of estrogen receptor ß might differ by the subtype of 
stomach  adenocarcinoma,  specifically  signet  ring  adenocarcinoma.  So 
estrogen receptor status should be studied along with the histopathological 
subtypes of cancer.
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HYPOTHESIS
Abnormalities  of  the  cell  cycle  are  said  to  be  the  cause  for  the 
initiation and maintainance of malignancy. Normally several key proteins 
are essential  for maintainance of homology. When there is aberrance in 
expression  of  any  of  the  key  proteins,  abnormal  cell  cycling  sets  in, 
malignancy ensues.
Estrogen found to increase apoptosis in human gastric cancer cells 
and  trefoil  peptide  expression  which  helps  in  mucosal  protection  of 
stomach. Estrogen also has growth inhibition on estrogen receptor positive 
esophageal cancer cells.
We have attempted here to identify positivity of estrogen receptor 
status in esophageal and gastric malignancy, which may pave the way for 
hormonal manipulation both in therapeutic and preventive aspects in future.
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REVIEW OF LITERATURE
 In 1960, Jensen et al., reported for the first time, that after injecting a 
physiological dose of  3H E2 into the Hypoderm of a young mouse; 
the amount of 3H E2 found in the tissues of uterus, vagina and other 
parts was greater than that found in blood plasma. This proved for 
the first time that estrogen receptor protein was present in tissues of 
uterus and vagina (31).
 In  1961,  Folca  et  al., found  that  women  who would  respond  to 
endocrine  ablation  in  breast  cancer,  had  a  greater  uptake  of 
radioactive  hexestrol,  a  synthetic  estrogen  compound  in  their 
neoplasm (45).
 In 1983, Tokunaga et al, first reported estrogen receptor expression 
in  Gastric  cancer  and  its  role  in  gastric  carcinogenesis  remained 
unknown (46).
 In  1987,  Matsuoka,  H.  et  al. established  that  cell  lines  from 
established squamous cell  esophegeal  carcinoma was found to be 
moderately responsive to hormones, being inhibited by estrogen and 
enhanced by testosterone (52).
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 In 1988, Yokozaki H.  et al. Department of Pathology, Hiroshima 
University,  School  of  Medicine,  Japan  established  that  estrogen 
receptor  immunoreactivity  positive  gastric  schirrous  carcinomas 
showed a much worse prognosis than those with estrogen receptor 
immunoreactivity negative gastric schirrous carcinoma (53).
 In  1989,  Utsumi  Y,  Nakamura  T.  et  al. second  department  of 
Surgery Shimane Medical University, Izumo, Japan established that 
inhibitory effect  of  estrogen on the  growth of  human esophageal 
carcinoma cell line was mediated by estrogen receptor (18).
 In  1991,  Yasuo  Utsumi,  M.D.  Teruhisa  Nakamura  M.D.  et  al. 
established  that  growth  inhibition  of  estrogen  receptor  positive 
esophageal  cancer cell line by 17ß estradiol is mediated by signal 
transduction and induced by the estrogen. estrogen receptor system 
(18).
 In  1998,  H.L.  Waldum  et  al.,  Department  of  Medicine  and 
Pathology,  University  Hospital,  and  Institute  of  Physiology  and 
Biomedical Engineering and Morphology, Norwagean University of 
Science and Technology -  Norway, established that  hormones  by 
stimulating growth increase the probability of mutation in their target 
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cell  and  also  they  stimulate  the  growth  of  mutated  cell.  Thus 
hormones are complete carcinogens (45).
 In  1998,  Korenja  D et  al.  Department  of  Surgery,  Fukuoka City 
Hospital,  Japan  established  that  sex  hormone  receptor  negative 
tumours  have  a  higher  proliferative  activity  than  sex  hormone 
receptor  positive  tumor  in  Human adenocarcinoma of  the  Gastro 
intestinal tract (49).
 In 1999, Oshima CT, Wonraht DR et al. Fundacao Oncocentro Sao 
Paulo,  Clinical  and Cirurgica  Unifesp-Epm Brazil  established  the 
presence  of  estrogen  receptor  in  gastric  cancer  patients,  50%  in 
males patients, and 75% in female patients and 62.5% in both males 
and  females  of  adjacent  normal  gastric  tissues  by 
immunohistochemical method.
 In 2001, Campbell Thompson M. Department of Medicine, College 
of  Medicine,  University  of  Florida,  gianesville,  Florida,  USA 
established  that immunolocalization of estrogen receptor alpha and 
beta in gastric epithelium and enteric neurons and its relations to 
sexual dimorphism in gastric acid secretion (36).
 In 2002, Matsuyama S et al., Department of Surgery, Saja Medical 
School, Saja city, Saga, Japan established that estrogen receptor  ß 
was  found  to  be  expressed  in  human  gastric  adenocarcinoma 
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including  normal  gastrointestinal  tract.  Among  signet  ring  cell 
adenocarcinomas of the stomach, cytoplasm were stained, in addition 
to nuclei.
 In  2002,  Takano  N,  Tizuke  N,  Hazama  S.  et  al. Department  of 
Surgery  Yamaguchi  University  School  of  Medicine,  Yamaguchi, 
Japan established that altered expression of estrogen receptor  - alpha 
and  estrogen  receptor   beta  in  gastric  cancer  compared  with 
corresponding normal gastric tissues. They also established altered 
expression to increased metastatic potential in gastric cancer (42).
 In  2003,  Xin  Han  Zhao  et  al. Department  of  Oncology,  Xijing 
Hospital,  Fourth  Military  Medical  University,  Xian  Shaanxi 
Province, China established the expression of estrogen receptor beta 
in normal gastrointestinal tract. The effects of estrogen in stomach 
cancer and normal tissues might be mediated by estrogen receptor 
beta  and the role of  estrogen receptor  -  beta might  differ  by the 
subtype  of  stomach  adenocarcinoma  especially  signet  ring  cell 
adenocarcinoma. They proved estrogen receptor positive rate of 40% 
and estrogen receptor  mRNA positive rate of 80% in gastric cancer. 
They also established that estrogen receptor mRNA expression has 
greater value than estrogen receptor  protein expression in clinical 
application, because of high sensitivity of insitu hybridisation and 
strong expression in gastric cancer which might be used to judge the 
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prognosis  of  tumour  and  predict  the  effectiveness  of  endocrine 
therapy for gastric cancer (19).
 In 2004, In Sook Woo et al., Department of Internal Medicine, College 
of Medicine, Catholic University, Seoul, Korea established that loss of 
estrogen receptor α expression located at chromosome 6 is associated 
with hypermethylation near its promotor region ATG start codon in 
Gastric  Cancer  cell  lines,  which  leads  to  gene  silencing  including 
tumour suppressor gene (46).
 In 2004. Mats Lindblad  et al., Department of Surgical Sciences and 
Pathology and Cytology, Karolinsks University Hospital Stockholm, 
Sweden established that estrogen prevents gastric cancer in a cohort 
of men heavily exposed to estrogen (47).
 In 2005, Ratna K. Vadlamudi Ph.D., Seetharaman Balasenthil Ph.D. 
et al., Department of Molecular and Cellular Oncology, the University 
of  Texas,  M.D.  Anderson  Cancer  Centre,  Houston,  Texas,  USA 
established  estrogen  receptor  beta  expression  in  salivary  duct 
adenocarcinoma. They also proved that estrogen receptor ß staining 
was nuclear and occasionally cytoplasmic in tumour cells. They also 
established that estrogen receptor  ß in absence of estrogen receptor α 
may play a tumour  suppressor function  and may provide a novel 
therapeutic target, using specific agonist in salivary ductal carcinoma 
(48).
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STUDY DETAILS
Type of Study
Prospective Descriptive Experimental Study.
Study Duration
Jan 1, 2005 to December 31, 2005.
Collaborating Institutions
1. Department of Surgery, Government Royapettah Hospital, Kilpauk 
Medical College, Chennai - 600 010, India.
2. Department of Surgical Gastroenterology, Government Royapettah 
Hospital, Kilpauk Medical College, Chennai - 600 010, India.
3. Division  of  Immuno  Histochemistry,  R&D  Histopath  Lab, 
Mylapore, Chennai - 600 004, India.
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DETAILS OF MATERIAL AND 
EXPERIMENTAL DESIGN
Tissue Specimens
Formalin fixed, paraffin embedded, tissue from endoscopic biopsy of 
esophageal  and  gastric  malignancy  patients  were  used  for  this  study. 
Histological  sections  were  studied  by  the  collaborating  pathologist  at 
Immuno histochemistry  division of  the R&D Histopath Lab,  Mylapore, 
Chennai - 4.
Technique of Detection
Immunohistochemistry  is  a  multi  step  process  that  requires 
specialized processing of the tissue, the selection of appropriate reagents 
and  interpretation  of  the  stained  tissue  sections.  In  general, 
immunohistochemistry staining techniques allow for the visualization of 
antigens, by sequential application of a specific antibody to the antigen, a 
secondary antibody to the primary antibody which serves as a link between 
the  primary  antibody  and  streptavidin  enzyme  conjugate,  an  enzyme 
conjugate and a chromogenic substrate.  The enzymatic activation of the 
chromogen results in a visible product at the antigen site.
We  have  used  this  method  in  identifying  estrogen  receptor  in 
esophageal and gastric malignancies, in our study.
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MATERIALS AND METHODS
The primary antibody mouse anti-estrogen receptor clone - ER-7G5 
was  obtained  from  Zymed  Laboratories  Inc,  South  Sanfrancisco,  CA 
94080, USA. The necessary reagent,  buffers  and humidifying chambers 
were  utilized  from the  Immunohistochemistry  division  R&D  Histopath 
Lab; Mylapore, Chennai-4. The primary monoclonal antibody is generated 
in Ascitic fluid, protein A purified. The vial is filled to 0.5 ml with reagent 
containing PBS, 1% BSA, and 0.1% sodium azide.
Tissue section of 5 microns cut with the help of Leica microtome. 
They  were  applied  to  Poly-L-Lysine  precoated  slides.  The  following 
staining protocol was followed. Dewaxing done in xylene bath and sections 
were brought  to  water  through graded alcohol.  They were subjected  to 
microwave antigen retrieval in citrate buffer of pH6 for 30 mins. To block 
non specific reactivity and staining from endogenous peroxidase, sections 
were incubated with hydrogen peroxide for 5 minutes. 
After  rinsing the slides were incubated at  room temperature with 
estrogen receptor primary antibody for 1½ hrs. The slides were washed and 
biotinylated link was applied and incubated for 30 minutes. The sections 
were incubated in biotinylated streptavidin HRP for 30 minutes. In between 
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these stages, the slides were rinsed in 10mM phosphate buffered saline. 
DAB, a substrate chromogen was applied and the slides were incubated for 
5  minutes.  The  slides  were  thoroughly  rinsed  and  counterstained  with 
Mayer's Hematoxylin for 30 seconds and then covered with glycerol jelly 
and cover slip applied.
Throughout the procedure 98 to 100% humidity was maintained in a 
humid  chamber.  After  the  above  procedure,  the  slides  were  ready  for 
screening.
Immunohistochemistry  stained  positive  cells,  look  brown  and 
negative cells look blue.
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EVALUATION OF STAINING
Intensity of Staining
0 = No staining 
1+ = weak, but definitive staining
2+ = Positive
3+ = Strong Positive
(Histopathology, Vol.18, No.6; June 1991).
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DATA ANALYSIS
Statistical Methods
The significance of the association between variables was tested by 
the  χ2 test. The variables included in univariate statistical analysis were 
gender, age, degree of differentiation, location of the tumour, intensity of 
staining of estrogen receptor expression levels. All p values reported are for 
a two-sided test and the level of significance was set at 0.05, SPSS version 
14 software was used for the statistical analysis. This was done with help of 
the statistical analysts, in The Institute of Community Medicine, Madras 
Medical  College,  Chennai  -  600  003.  The  basic  data  collected  during 
endoscopy regarding the age, sex and the location of the tumour and degree 
of differentiation in the esophagus and stomach were analysed with regards 
to  the  staining  of  estrogen  receptor  expression  obtained  after 
immunostaining.
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STATEMENT  OF LIMITATIONS
This study is based on, a limited number of patients. A detailed study 
of more subjects, in relation to histopathology of cancer and lymphnode 
status and followup for a longer duration will augment the validity of the 
data.
Many foreign researchers are  of the opinion that, compared with 
other  methods  in  examining  estrogen  receptor  protein,  the  molecular 
hybridization  in  examining  estrogen  receptor  mRNA  has  a  higher 
sensitivity  (41,42)  and  estrogen  receptor  mRNA expression  has  greater 
value than estrogen receptor protein expression in clinical application. This 
is because of high sensitivity of insitu hybridization and the strong estrogen 
receptor mRNA expression in gastric cancer, which can be used to judge 
the prognosis of tumour and predict the effectiveness of endocrine therapy 
in gastric cancer.
ETHICAL ISSUES INVOLVED
The study was done in tissue obtained from upper gastrointestinal 
endoscopy. No ethical conflicts are involved in this study.
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ANALYSIS
PATIENT CHARACTERISTICS
n = 50
Characteristics No. of patients
1. Gender
 Carcinoma Esophagus = 19
Male = 8
Female = 11
 Carcinoma Stomach = 31
Male = 23
Female = 8
2. Age
Carcinoma Esophagus = 45-75 years
Carcinoma Stomach = 37-84 years
25
3. Site
Carcinoma Esophagus = 19
Carcinoma Stomach = 31
4. Histopathology
Squamous Cell Carcinoma = 16
Adenocarcinoma = 34
5. Differentiation
 Carcinoma Esophagus
Well differentiated = 8
Moderately differentiated = 6
Poorly differentiated = 5
 Carcinoma Stomach
Well differentiated = 16
Moderately differentiated = 11
Poorly differentiated = 4
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OBSERVATIONS
AGE BASED OBSERVATION
CARCINOMA ESOPHAGUS
Age
Intensity of Staining
0 1+ 2+ 3+ Total patients
Total 
positivity
41-50 1 1 0 1 3 2
51-60 1 0 1 1 3 2
61-70 3 1 2 1 7 4
71-80 1 3 1 0 5 4
81-90 0 1 0 0 1 1
Total 6 6 4 3 19 13
The above data was statistically analysed. χ2 test = 34. 443, df =25, 
p.  value=  0.025,  CI  =  0.022-0.028.  The  study  patients  predominantly 
belonged to the 7th and 8th decade. The positivity was more appreciated in 
seventh and eight  decade and cent  percent estrogen receptor expression 
seen in 9th decade.
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AGE BASED OBSERVATION
CARCINOMA ESOPHAGUS
0 1+ 2+ 3+ Total Positivity
0
2
4
6
8
10
12
14
16
18
20
41-50
51-60
61-70
71-80
81-90
Total
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AGE BASED OBSERVATION
CARCINOMA STOMACH
Age
Intensity of Staining
0 1+ 2+ 3+ Total patients
Total 
positivity
31-40 1 0 0 0 1 0
41-50 4 1 1 1 7 3
51-60 4 2 3 0 9 5
61-70 5 0 2 0 7 2
71-80 2 1 3 0 6 4
81-90 0 1 0 0 1 1
Total 16 5 9 1 31 15
The above data  was statistically analysed. χ2 test = 34.443, df =25,  
p.value=  0.025,  CI  =  0.022-0.028.  The  study  patients  predominantly 
belonged 6th  and 7th decade. The estrogen receptor positivty was more in 
sixth decade and eight decade.
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AGE BASED OBSERVATION 
CARCINOMA STOMACH
0 1+ 2+ 3+ Total 
patients
Total 
positivity
0
5
10
15
20
25
30
35
31-40
41-50
51-60
61-70
71-80
81-90
Total
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SEX BASED ESTROGEN RECEPTOR STATUS
ESOPHAGEAL CARCINOMA
Sex
Intensity of Staining
0 1+ 2+ 3+
Total 
patients
Total 
positivity
Male 2 3 3 0 8 6
Female 4 3 1 3 11 7
Total 6 6 4 3 19 13
The  above  data   was  statistically  analysed.  χ2 test  =  0.45  
df = 1, p.value= 1.000. The percentage of positivity of estrogen receptor 
had no difference among sexes in carcinoma esophagus. 
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SEX BASED DISTRIBUTION
CARCINOMA ESOPHAGUS 
0 1 2 3 Total Positivity
0
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4
6
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20
Male
Female
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SEX BASED ESTROGEN RECEPTOR STATUS
STOMACH CARCINOMA
Sex
Intensity of Staining
0 1+ 2+ 3+ Total 
patients
Total 
positivity
Male 12 4 6 1 23 11
Female 4 1 3 0 8 4
Total 16 5 9 1 31 15
χ2 test = 0.45, df = 1, p.value= 1.000. The percentage of estrogen 
receptor positivity is more in females when compared to males.
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 SEX BASED DISTRIBUTION
CARCINOMA STOMACH
0 1 2 3 Total Positivity
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5
10
15
20
25
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ORGAN BASED ESTROGEN RECEPTOR STATUS
Organ
Intensity of Staining
0 1+ 2+ 3+
Total 
patients
Total 
positivity
Esophagus 6 6 4 3 19 13
Stomach 16 5 9 1 31 15
Total 22 11 13 4 50 28
χ2 test  =  1.923,  df  =  2,  p.value=  0.461,  CI  =  0.452-0.471.  The 
percentage of estrogen receptor positivity is more in esophageal carcinoma 
when compared to stomach carcinoma.
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ORGAN BASED DISTRIBUTION
0 1 2 3 Total Positivity
0
10
20
30
40
50
60
Total
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HISTOPATHOLOGY BASED ESTROGEN 
RECEPTOR STATUS
ESOPHAGEAL CARCINOMA
Carcinoma
Intensity of Staining
0 1+ 2+ 3+
Total 
patients
Total 
positivity
Squamous 
cell 
carcinoma
5 6 2 3 16 11
Adeno 
carcinoma
1 0 2 0 3 2
Total 6 6 4 3 19 13
The above data was statistically analysed.  χ2 test = 1.552, df =1,  
p.value= 0.240 The percentage of positivity for estrogen receptor, remains 
same for both histopathological types in carcinoma esophagus.
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HISTOLOGY BASED ER STATUS
CARCINOMA ESOPHAGUS
0 1 2 3 Total Positi
vity
0
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4
6
8
10
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14
16
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20
Squamous carcinoma Adenocarinoma Total
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GASTRIC CARCINOMA
Carcinoma
Intensity of Staining
0 1+ 2+ 3+ Total patients
Total 
positivity
Adeno 
carcinoma
16 5 9 1 31 15
The above data was statistically analysed.  χ2 test = 1.552, df =1,  
p.value  =  0.240.  The  estrogen  receptor  positivity  is  48%  in  Gastric 
adenocarcinoma.
0 1 2 3 Total Positivity
0
5
10
15
20
25
30
35
Gastric adenocarcinoma and E R status
Adenocarcinoma
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DIFFERENTIATION BASED ESTROGEN 
RECEPTOR STATUS
ESOPHAGEAL CARCINOMA 
Differentiation 
type
Intensity of Staining
0 1+ 2+ 3+ Total 
patients
Total 
positivity
Well 
differentiated 
3 3 1 1 8 5
Moderately 
differentiated
2 2 0 2 6 4
Poorly 
differentiated
1 1 3 0 5 4
Total 6 6 4 3 19 13
The above data was statistically analysed.  χ2 test = 0.821 df=2,  
p.value= 0.748, CI = 0.739 - 0.756. Estrogen receptor positivity is more in 
poorly differentiated type than others.
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DIFFERENTIATION BASED E R STATUS
CARCINOMA ESOPHAGUS
0 1 2 3 Total Positi
vity
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20
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DIFFERENTIATION BASED ER STATUS
GASTRIC CARCINOMA
Differentiation 
type
Intensity of Staining
0 1+ 2+ 3+
Total 
patients
Total 
positivity
Well 
differentiated 
9 2 4 1 16 7
Moderately 
differentiated
5 2 4 0 11 6
Poorly 
differentiated
2 1 1 0 4 2
Total 16 5 9 31 15
The above data was statistically analysed.  χ2 test = 0.821 df=2,  
p.value= 0.748, CI = 0.739 - 0.756. Estrogen receptor positivity is more in 
moderately differentiated type than others.
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STOMACH ADENOCARCINOMA 
DIFFERENTIATION BASED E R STATUS
0 1 2 3 Total Positivity
0
5
10
15
20
25
30
35
Well diff
Mod diff
Poor diff
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ESTROGEN RECEPTOR STATUS IN NUCLEUS
AND CYTOPLASM
CARCINOMA ESOPHAGUS
Location of 
positivity
Intensity of Staining
0 1+ 2+ 3+ Total patients
Total 
positivity
Cytoplasm 6 6 4 3 19 13
Nucleus 11 7 1 0 19 8
Estrogen receptor positivity is more in cytoplasm than in nucleus.
0 1 2 3 Total Positivity
0
2
4
6
8
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16
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20
Carcinoma Esophagus - Cellular location based ER status
Cytoplasm
Nucleus
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ESTROGEN RECEPTOR STATUS IN NUCLEUS
AND CYTOPLASM
CARCINOMA STOMACH
Location of 
positivity
Intensity of Staining
0 1+ 2+ 3+ Total patients
Total 
positivity
Cytoplasm 16 5 9 1 31 15
Nucleus 23 8 0 0 31 8
Estrogen receptor positivity is more in cytoplasm than in nucleus.
0 1 2 3 Total Positivity
0
5
10
15
20
25
30
35
Gastricadenocarcinoma - Cellular Location based E R status
Cytoplasm
Nucleus
45
DISCUSSION
COMPARISON OF THIS STUDY WITH 
SIMILAR STUDIES 
CARCINOMA STOMACH
Study Group
No. of 
Pa
tie
nt
s 
(n)
Estrogen Receptor 
Immunopo
sitivity
Matsuyama et al (41) 29 100%
Zhao XH et al (19) 30 40%
Takano et al (43) 41 60%
Korenaga D et al  (49) 23 56%
Oshima CT et al (14) 16 62.5%
Yokozaki H et al (50) 108 27.8%
Chu PG et al (51) 30 0%
The positive expression of Estrogen receptors in our Study in 48% 
and the total number of patients is 31 which is almost comparable with 
most of the Japanese study mentioned above. Some of the above studies 
having  higher  estrogen  receptor  positivity  used  Charcoal  adsorption 
method than immunohistochemistry.
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UNANSWERED QUESTIONS
1. Inspite of extensive molecular advances, no single mechanism or 
pathway has been solely implicated in any of the known human 
cancers. Hence with the present knowledge base available it is 
prudent for anyone to choose multiple drugs.  This will ascertain the 
blockade of complex carcinogenetic pathway, is near complete to 
achieve maximal response. It remains to be known, whether isolated 
estrogen receptor modulation or a multimodal therapy is essential to 
show a definitive survival benefit.
2. Recently,  the  subtypes  of  estrogen receptors   and   are  being 
found to be expressed in normal gastro intestinal tract and gastric 
cancers. The mRNA  for both the subtypes  has been detected in 
the  gastric  mucosa..  The  cellular  distribution  of  the  estrogen 
receptor  in  various  organelles  determine  the  outcome,  on  the 
influence of estrogen. The distribution of estrogen receptor  and  
are almost  similar  in fundic  cells  whereas in antrum   alone is 
better expressed. This indirectly suggests, estrogen inhibits gastric 
acid secretion via genomic effects in fundic parietal cells through 
either ER subtypes and antral cells via ER . The expression of ER 
in  enteric  neurons  indicate  that  estrogen  effects  could  also  be 
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mediated  through  neurogenic  effects.  This  clearly  implies  that 
multiple  cells  expressing  ER,  contribute  to  the  modulation  of 
gastric function. Henceforth, now after detecting so much of ER 
positivity, it remains unanswered, whether achlorhydria caused by 
atrophic gastritis is indirectly controlled by ER. So the role of ER 
modulators in these type of premalignant conditions is yet to be 
quantified. 
3. Work on the effect  of 17   estradiol and esophageal cancer cell 
lines have clearly shown, the increase in cell doubling time from 
20 to 32 hrs by estrogen, when compared to untreated control. In 
reality, any tumour cell line cultured in vitro, has definitive less 
multifactorial influences when compared to malignancy in a living 
patient. The invitro to invivo translation of the above hypothesis 
will  take  a  longer  time,  so  the  ultimate  survival  benefit,  from 
estrogens in esophageal malignancy is yet to be known.    
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SUMMARY AND CONCLUSION
Estrogen receptor is a nuclear transcription factor, that is a member 
of  the  steroid  receptor  superfamily.  Recent  advances  in  the  molecular 
biology, have helped us in evaluating the presence of estrogen receptor in 
upper  gastro intestinal  malignancies,  indicating the role  of  hormones  in 
therapeutic aspects.
We have done this study to identify the presence of estrogen receptor 
in upper gastrointestinal malignancies. The tissue obtained by endoscopic 
biopsy was utilised for this study. The histopathology was confirmed. The 
tumour  tissue  was  subjected  to  immunohistochemistry  examination  for 
identification of estrogen receptor. Data obtained were based on various 
parameters.
In carcinoma esophagus out of the 19 patients studied 11 are females 
(55%) and 8 are males (45%). Patients with estrogen receptor positivity 
contributed  to  68.42%  and  was  more  when  compared  to  gastric 
malignancy.  90%  of  patients  were  between  41-80  years  age  group. 
Estrogen  receptor  positivity  remained  same  in  around  68%  between 
adenocarcinoma and squamous cell carcinoma. Poorly differentiated cancer 
showed high estrogen receptor positivity (80%) when compared to other 
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differentiated types. Estrogen receptor positivity was more in the cytoplasm 
when compared to nuclear positivity 
In carcinoma stomach out of 31 patients studied 23 were male (75%) 
and 8 were female (25%). Out of 31 patient, 15 were positive for estrogen 
receptor (48.38%). 90% of patients were between 41-80 years age group. 
Estrogen receptor positivity is 48% in gastric adenocarcinoma. Moderately 
differentiated type has higher estrogen receptor positivity (54.5%) when 
compared  to  other  differentiated  types  (42-50%).  Estrogen  receptor 
positivity is more in cytoplasm when compared to nuclear positivity.
Identifying the estrogen receptor  positivity  will  help in  hormonal 
manipulation of the upper gastrointestinal malignancies. In future it may be 
of use in detecting premalignant conditions or early detection of cancerous 
transformation in high risk group. So it can possibly be used as a "screening 
tool". 
In advanced diseases, hormone therapy can be tried "to contain" 
the disease. We will be able to draw a firm conclusion from large volume 
studies on Indian population, with long time patients follow up. 
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P R I M A R Y  A N T I B O D Y  A N D  R E A G E N T S  
U S E D  I N  T H I S  S T U D Y
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E S T R O G E N  R E C E P T O R  P O S I T I V E  
G A S T R I C  M A L I G N A N C Y  
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E S T R O G E N  R E C E P T O R  P O S I T I V E  
E S O P H A G E A L  M A L I G N A N C Y  
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E S T R O G E N  R E C E P T O R  N E G A T I V E  
U G I  M A L I G N A N C Y  
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CUMULATIVE RESULTS
Sl.
No
Patient Endoscopy 
I/D Age Sex Site of Biopsy Histopathology Differentiation
Estrogen 
Receptor 
Status
Grading
Cytoplasm Nucleus
1. 16/05 63 M Esophagus Squamous cell 
carcinoma
Moderately 
Differentiated
Positive 1+ 1+
2. 22/05 47 F Esophagus Squamous cell 
carcinoma
Well Differentiated Negative -ve -ve
3. 192/05 75 F Esophagus Squamous cell 
carcinoma
Well Differentiated Positive 1+ -ve
4. 321/05 84 F Esophagus Squamous cell 
carcinoma
Well Differentiated Positive 1+ -ve
5. 371/05 76 F Esophagus Squamous cell 
carcinoma
Well Differentiated Positive 1+ 1+
6. 24/05 67 M Esophagus Squamous cell 
carcinoma
Poorly Differentiated Positive 2+ 1+
7. 49/05 48 M Esophagus Squamous cell 
carcinoma
Moderately 
Differentiated
Positive 1+ -ve
8. 479/05 64 F Esophagus Squamous cell 
carcinoma
Well Differentiated Negative -ve -ve
9. 05/05 63 F Esophagus Squamous cell 
carcinoma
Poorly Differentiated Positive 2+ 1+
10. 584/05 60 F Esophagus Squamous cell 
carcinoma
Moderately 
Differentiated
Positive 3+ 2+
11. 606/05 52 F Esophagus Squamous cell 
carcinoma
Moderately 
Differentiated
Positive 3+ 1+
12. 328/05 64 M OG Junction Squamous cell 
carcinoma
Moderately 
Differentiated
Negative -ve -ve
13. 610/05 65 F Esophagus Squamous cell 
carcinoma
Poorly Differentiated Negative -ve -ve
14. 112/05 71 M Esophagus Squamous cell 
carcinoma
Poorly Differentiated Positive 1+ -ve
15. 161/05 71 M Esophagus Squamous cell 
carcinoma
Moderately 
Differentiated
Negative -ve -ve
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16. 612/05 50 F Esophagus Squamous cell 
carcinoma
Well Differentiated Positive 3+ 1+
17. 358/05 60 M OG Junction Adenocarcinoma Well Differentiated Positive 2+ 1+
18. 182/05 55 F OG Junction Adenocarcinoma Well Differentiated Negative -ve -ve
19. 253/05 75 M OG Junction Adenocarcinoma Poorly Differentiated Positive 2+ -ve
20. 104/05 68 F Stomach Adenocarcinoma Moderately 
Differentiated
Positive 2+ 1+
21. 39/05 52 M Stomach Adenocarcinoma Poorly Differentiated Positive 1+ 1+
22. 56/05 83 M Stomach Adenocarcinoma Well Differentiated Positive 1+ -ve
23. 120/05 67 F Stomach Adenocarcinoma Moderately 
Differentiated
Positive 2+ 1+
24. 66/05 65 M Stomach Adenocarcinoma Moderately 
Differentiated
Negative -ve -ve
25. 75/05 45 M Stomach Adenocarcinoma Moderately 
Differentiated
Positive 2+ -ve
26. 180/05 59 F Stomach Adenocarcinoma Well Differentiated Positive 2+ 1+
27. 220/05 37 F Stomach Adenocarcinoma Well Differentiated Negative -ve -ve
28. 111/05 73 M Stomach Adenocarcinoma Well Differentiated Positive 2+ -ve
29. 231/05 64 M Stomach Adenocarcinoma Moderately 
Differentiated
Negative -ve -ve
30. 295/05 52 M Stomach Adenocarcinoma Moderately 
Differentiated
Positive 2+ -ve
31. 375/05 55 M Stomach Adenocarcinoma Well Differentiated Negative -ve -ve
32. 347/05 41 M Stomach Adenocarcinoma Moderately 
Differentiated
Positive 1+ -ve
33. 277/05 75 F Stomach Adenocarcinoma Poorly Differentiated Negative -ve -ve
34. 284/05 58 F Stomach Adenocarcinoma Well Differentiated Negative -ve -ve
35. 380/05 50 M Stomach Adenocarcinoma Well Differentiated Negative -ve -ve
36. 404/05 75 M Stomach Adenocarcinoma Well Differentiated Negative -ve -ve
37. 442/05 42 M Stomach Adenocarcinoma Moderately 
Differentiated
Negative -ve -ve
38. 467/05 51 M Stomach Adenocarcinoma Moderately 
Differentiated
Positive 1+ 1+
39. 388/05 76 F Stomach Adenocarcinoma Well Differentiated Positive 1+ -ve
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40. 470/05 79 M Stomach Adenocarcinoma Well Differentiated Positive 2+ 1+
41. 472/05 50 M Stomach Adenocarcinoma Well Differentiated Positive 3+ 1+
42. 481/05 47 M Stomach Adenocarcinoma Well Differentiated Negative -ve -ve
43. 487/05 76 M Stomach Adenocarcinoma Poorly Differentiated Positive 2+ -ve
44. 499/05 59 M Stomach Adenocarcinoma Well Differentiated Negative -ve -ve
45. 480/05 58 F Stomach Adenocarcinoma Moderately 
Differentiated
Negative -ve -ve
46. 504/05 58 M Stomach Adenocarcinoma Well Differentiated Positive 2+ 1+
47. 509/05 69 M Stomach Adenocarcinoma Moderately 
Differentiated
Negative -ve -ve
48. 521/05 65 M Stomach Adenocarcinoma Well Differentiated Negative -ve -ve
49. 531/05 45 M Stomach Adenocarcinoma Poorly Differentiated Negative -ve -ve
50. 545/05 65 M Stomach Adenocarcinoma Well Differentiated Negative -ve -ve
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STUDY FORMAT
Name :
Age :
Sex :
a. Male
b. Female
Patient Endoscopy ID No.
Location of the tumor
a. Esophagus
b. OG Junction
c. Stomach
Histopathology of the tumor
Adenocarcinoma
Squamous cell Carcinoma
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Degree of Differentiation
a. Well differentiated
b. Moderately differentiated
c. Poorly differentiated
Immunohistochemistry
a. Positive
b. Negative
Degree of Staining
a. Grade 1+
b. Grade 2+
b. Grade 3+
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